Last reviewed · How we verify

GSP 301 Placebo NS pH 7.0

Glenmark Specialty S.A. · Phase 3 active Small molecule

GSP 301 Placebo NS pH 7.0 is a Small molecule drug developed by Glenmark Specialty S.A.. It is currently in Phase 3 development.

This is a placebo formulation with no active pharmaceutical ingredient.

At a glance

Generic nameGSP 301 Placebo NS pH 7.0
SponsorGlenmark Specialty S.A.
ModalitySmall molecule
PhasePhase 3

Mechanism of action

GSP 301 Placebo NS pH 7.0 is a neutral saline placebo control used in clinical trials. It contains no active drug substance and serves as a comparator arm in phase 3 studies to assess the efficacy and safety of an active investigational agent against an inert control.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about GSP 301 Placebo NS pH 7.0

What is GSP 301 Placebo NS pH 7.0?

GSP 301 Placebo NS pH 7.0 is a Small molecule drug developed by Glenmark Specialty S.A..

How does GSP 301 Placebo NS pH 7.0 work?

This is a placebo formulation with no active pharmaceutical ingredient.

Who makes GSP 301 Placebo NS pH 7.0?

GSP 301 Placebo NS pH 7.0 is developed by Glenmark Specialty S.A. (see full Glenmark Specialty S.A. pipeline at /company/glenmark-specialty-s-a).

What development phase is GSP 301 Placebo NS pH 7.0 in?

GSP 301 Placebo NS pH 7.0 is in Phase 3.

Related